Genomic Research Service Provider DNA Link Purchases 10 Ion Proton Sequencers

Genomic Research Service Provider DNA Link Purchases 10 Ion Proton Sequencers

PR Newswire

CARLSBAD, Calif., Dec. 11, 2012

CARLSBAD, Calif., Dec. 11, 2012 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announced that DNA Link Inc., a Korean genomic research
service provider, has placed an order to purchase ten Ion Proton™ Sequencers,
which are shipping immediately. To watch a short interview with DNA Link's
CEO, Dr. Jong Eun Lee, click here.

Life Technologies introduced the Ion Proton™ Sequencer in September and its
adoption by customers who are familiar with next-generation sequencing in both
the U.S. and emerging markets continues to grow significantly.

DNA Link's CEO, Dr. Jong Eun Lee,said he expects the $500 million that the
Korean government recently set aside to fund genomics research to drive
significantly more demand for the one-day sequencing turnaround that the Ion
Proton™ Sequencer delivers.

Dr. Lee, whose company processes tens of thousands of samples each year, said
the decision to select the Ion Proton™ System centered around three key
factors: speed, throughput and cost.

"It takes two weeks to get results with our current system, and it takes a
total of two to three months by the time the data are sequenced and
analyzed,"said Dr. Lee. "People just don't want to wait that long. Getting an
exome from sample to analysis in a day will give us a great competitive
advantage in the market."

Dr. Lee also said the Ion Proton™ Sequencer's simplified data analysis is a
significant advantage.

"The bioinformatics load from these big machines is just too much for us to
deal with," said Dr. Lee. "The more streamlined bioinformatics pipeline that
Ion Torrent offers will help us save time and turn around projects faster to
our customers."

Ion Torrent™ technology has emerged as the most outstanding value in
sequencing because of the relentless improvement in semiconductor sequencing
performance. These improvements now enable any sequencing application, from
targeted resequencing and microbial sequencing to exome sequencing and
transcriptome sequencing, and many others.

Life Technologies Korea's General Manager, Mrs. Soojin Seok, said she looked
forward to collaborating with Dr. Lee to expand his business as Korea moves
faster into genomics and sequencing.

"Since Dr. Lee purchased the Ion PGM™ Sequencer a year ago, we have been
working closely with him to demonstrate both the quality of Ion Torrent™
semiconductor sequencing technology, as well as the quality of support he will
receive from our Life Technologies staff in Korea," said Seok.

The Ion Torrent products discussed in this press release are for Research Use
Only; not for use in diagnostic procedures.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum, with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied
Biosystems®,Invitrogen™, Gibco®, Ambion®, Molecular Probes®, Novex®, and
TaqMan®. Life Technologies employs approximately 10,400 people and upholds its
ongoing commitment to innovation with more than 4,000 patents and exclusive
licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website:

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


Media Contacts:

Wes Conard
Life Technologies Corporation

Jon Kim
Life Technologies Korea

SOURCE Life Technologies

Press spacebar to pause and continue. Press esc to stop.